Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

CuspAI names 45 partners for lab access

3 min read
16:30UTC

CuspAI named more than 45 founding partners on Monday 20 July for a coalition it calls the AI Materials Foundry, pooling laboratories, data and compute alongside a $450m Series B.

TechnologyDeveloping
Key takeaway

CuspAI bought laboratory access with partnership terms, cheaper than instruments and binding on nobody.

CuspAI named more than 45 founding partners for an AI Materials Foundry on Monday 20 July, describing the coalition as "a global network of data, labs, compute and scientific expertise for the design of new materials"⁠1. The Cambridge company uses machine learning to predict compounds with specified properties, and announced the same day a $450m Series B at a $2.6bn valuation led by Kleiner Perkins and NEA, with Bezos Expeditions participating.

The names on the partner list own machines. Applied Materials, Tokyo Electron and Lam Research build the process equipment that fabricates semiconductors; Samsung and Hyundai Motor Group run production lines; Nvidia, Meta and Henkel are on it as well. A compound predicted on a Monday morning still needs a furnace to make it, a diffractometer to read its crystal structure and a technician to run both. That gap between prediction and synthesis is what the coalition addresses, and CuspAI has bought its way across with partnership terms rather than capital expenditure.

We reported the $400m term sheets in June at the same $2.6bn mark, so the valuation carries little a reader did not have a month ago. Fortune put the September 2025 Series A at $520m, citing a person familiar with the round⁠2, which makes the rise roughly fivefold in ten months while the physical work stayed in other people's buildings.

That list is CuspAI's own account of its own initiative, and we have not verified the membership independently. No partner has published a commitment of hours, materials or money. Coalitions of this shape have historically failed on scheduling rather than science: the United States ran into the same wall with the Materials Genome Initiative from 2011, where computational screening outran wet-lab throughput by orders of magnitude and queueing for instruments became the constraint. Until a partner names what it has contributed, the Foundry cannot be audited from outside.

Deep Analysis

In plain English

CuspAI is a Cambridge company that uses computer models to predict new materials, things like battery chemicals or semiconductor coatings, before anyone builds them in a lab. On 20 July it announced two things at once: it had raised $450m from investors, valuing the company at $2.6bn, and it had signed up more than 45 other companies, including the chipmaker Nvidia and the electronics giant Samsung, to a coalition called the AI Materials Foundry. The coalition matters because predicting a material on a computer is only half the job. Someone still has to build it in the real world and test whether it behaves as predicted, which needs specialist factory equipment CuspAI does not own. By signing up companies that already have that equipment, CuspAI is trying to move from prediction to a working product faster than it could by building the equipment itself.

Deep Analysis
Root Causes

A materials-discovery company that predicts compounds computationally still needs physical infrastructure to synthesise and validate them: furnaces, diffractometers and cleanroom fabrication lines that cost hundreds of millions of pounds to build and years to commission. CuspAI's own funding, even at $2.6bn, buys people and compute faster than it buys that infrastructure.

The Foundry substitutes equity-adjacent partnership for capital expenditure. Rather than building fabrication capacity it does not yet need at full scale, CuspAI buys access to partners who already operate it, in exchange for a public association with the round's momentum.

What could happen next?
  • Meaning

    CuspAI is treating laboratory and fabrication access, not cash, as the constraint it most needs to solve next.

    Immediate · Assessed
  • Risk

    A coalition with no disclosed capital or facility commitments from its 45-plus members could prove to be a marketing list rather than an operating partnership.

    Short term · Suggested
  • Precedent

    If the Foundry delivers a validated material to market, it would give other UK deep-tech companies a template for buying physical infrastructure access rather than building it.

    Medium term · Suggested
First Reported In

Update #12 · CuspAI pools 45 partners' labs and compute

CuspAI· 22 Jul 2026
Read original →
Causes and effects
This Event
CuspAI names 45 partners for lab access
A Cambridge company has assembled the largest industrial partner list of any UK startup this cycle by trading equity terms for bench time rather than buying instruments.
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.